Mylan's Antitrust Claims Nixed In Prilosec IP Suit
A federal judge has tossed Mylan Laboratories Inc.'s antitrust counterclaims and denied its bid for attorneys' fees in long-running multidistrict litigation brought by AstraZeneca AB accusing the generic-drug maker of infringing...To view the full article, register now.
Already a subscriber? Click here to view full article